Currently, there are 122.87M common shares owned by the public and among those 86.56M shares have been available to trade.
The company’s stock has a 5-day price change of -20.20% and -10.00% over the past three months. MRSN shares are trading -30.17% year to date (YTD), with the 12-month market performance down to -19.80% lower. It has a 12-month low price of $1.22 and touched a high of $6.28 over the same period. MRSN has an average intraday trading volume of 1.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -24.42%, -24.22%, and -33.18% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Mersana Therapeutics Inc (NASDAQ: MRSN) shares accounts for 66.09% of the company’s 122.87M shares outstanding.
It has a market capitalization of $200.13M and a beta (3y monthly) value of 1.38. The earnings-per-share (ttm) stands at -$0.61. Price movements for the stock have been influenced by the stock’s volatility, which stands at 13.55% over the week and 12.09% over the month.
Analysts forecast that Mersana Therapeutics Inc (MRSN) will achieve an EPS of -0.16 for the current quarter, -0.17 for the next quarter and -0.66 for current fiscal year. The lowest estimate earnings-per-share for the quarter is -0.21 while analysts give the company a high EPS estimate of -0.21. Comparatively, EPS for the current quarter was -0.16 a year ago. Earnings per share for the fiscal year are expected to increase by 60.21%, and 3.99% over the next financial year.
Looking at the support for the MRSN, a number of firms have released research notes about the stock. Citigroup stated their Buy rating for the stock in a research note on November 15, 2024, with the firm’s price target at $5. JP Morgan coverage for the Mersana Therapeutics Inc (MRSN) stock in a research note released on March 19, 2024 offered a Neutral rating with a price target of $5. Wedbush was of a view on February 29, 2024 that the stock is Outperform, while Guggenheim gave the stock Buy rating on February 29, 2024, issuing a price target of $7. BTIG Research on their part issued Buy rating on February 29, 2024.
